VTYX
Ventyx Biosciences Inc

1,658
Loading...
Loading...
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
82

Frequently Asked Questions

What is Market Cap of Ventyx Biosciences Inc?
What is the 52-week high for Ventyx Biosciences Inc?
What is the 52-week low for Ventyx Biosciences Inc?
What is Ventyx Biosciences Inc stock price today?
What was Ventyx Biosciences Inc stock price yesterday?
What is the PE ratio of Ventyx Biosciences Inc?
What is the Price-to-Book ratio of Ventyx Biosciences Inc?
What is the 50-day moving average of Ventyx Biosciences Inc?
How many employess does Ventyx Biosciences Inc has?

Latest VTYX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.